Health insurance allowance possible for Visudyne

Published: 2004-03-11 06:56:00

Updated: 2004-03-11 06:56:00

The Ministry of Health and Welfare announced recently revised terms for health insurance allowance for Novartis Korea's Visudyne (verteporfin) for the treatment of predominantly classic form of age-related macular degeneration (AMD) and similar but distinct condition associated with progressive n...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK